Evidence at the Speed of Science: How Leading Pharma Is Putting AI to Work in R&D | PharmExec
Takeda's Head of Computational & Systems Biology joins Causaly to share how AI evidence synthesis is compressing R&D timelines from indication expansion to Phase 3 decisions. Hear the real use cases,. . .
Takeda's Head of Computational & Systems Biology joins Causaly to share how AI evidence synthesis is compressing R&D timelines from indication expansion to Phase 3 decisions. Hear the real use cases, real results, and real lessons from the frontline of pharma AI adoption. Register Free:https://www. pharmexec. com/pe_w/speed-of-scienceEvent Overview:Takeda's Head of Computational & Systems Biology joins Causaly to share how AI evidence synthesis is compressing R&D timelines from indication expansion to Phase 3 decisions. Hear the real use cases, real results, and real lessons from the frontline of pharma AI adoption. Key Learning ObjectivesUnderstand why purpose-built scientific AI outperforms general LLMs for R&DGain insight from real use cases: indication expansion, MoA analysis, Phase 3 supportKnow how to scale AI adoption from early pilots to team-wide practiceWho Should AttendR&D Scientists, Computational Biologists, Heads of Drug Discovery, Medical Affairs Leaders, Heads of R&D, Chief Scientific OfficersTranslational Scientists, R&D VPs and CSOs, Regulatory Affairs, Clinical Operations, BioinformaticiansSpeakers:Joe Gigliotti, MD, MBAStrategic Client PartnerCausalyJoe Gigliotti, MD, MBA is Strategic Client Partner at Causaly, the agentic AI platform for life sciences. A former Partner at Boston Consulting Group and graduate of Geisel School of Medicine at Dartmouth, Joe brings deep clinical and strategic expertise to his work with enterprise R&D teams. At Causaly, he focuses on helping organizations move from isolated AI pilots to durable, team-wide scientific capability. Vinayagam ArunachalamSenior Director, Head of Computational & Systems BiologyTakedaVinayagam Arunachalam is Senior Director and Head of Computational & Systems Biology in Takeda's GI² Early Clinical Development unit. With 18+ years spanning Pfizer, Harvard Medical School, and the German Cancer Research Center, Vinu leads strategies for target identification, biomarker discovery, and disease pathway analysis. He has published 30+ peer-reviewed articles and authored a book on AI/ML in life sciences. Register Free:https://www. pharmexec. com/pe_w/speed-of-science